Pegfilgrastim-Apgf (Nyvepria): Biosimilar USFDA Approval for the Treatment of Chemotherapy-induced Febrile Neutropenia and Current Updates on Clinical Trials

被引：2
|
作者：
Ali, Faraat [1 ]
Sharma, Kamna [2 ]
Ali, Asad [3 ]
机构：
[1] Botswana Med Regulatory Authority, Lab Serv, Plot 112,Int Finance Pk, Gaborone, Botswana
[2] Indo Soviet Friendship Coll Pharm, Dept Pharmaceut Anal, Moga, Punjab, India
[3] Jamia Hamdard, Sch Chem & Life Sci, Dept Chem, New Delhi, India
来源：
CURRENT DRUG TARGETS | 2022年 / 23卷 / 09期
关键词：
Pegfilgrastim-apgf (Nyvepria); biosimilar; febrile neutropenia; non-myeloid cancer; FDA; anticancer drugs; ONCOLOGY; SAFETY; CT-P6;
D O I：
10.2174/1389450123666220408101152
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Pegfilgrastim-apgf (nyvepria) was currently approved by FDA for the treatment of febrile neutropenia associated with non-myeloid malignancies receiving myelosuppressive anticancer drugs. It was developed by Pfizer, USA. It is a PEGylated leukocyte growth-stimulating factor indicated to reduce the incidence of febrile neutropenia in patients receiving anticancer drugs. Nyvepria is biosimilar to pegfilgrastim, approved by FDA on June 10, 2020. It is the fourth FDA-approved drug for the treatment of infection exhibiting febrile neutropenia. This review abridges the indicators in the development of nyvepria foremost to approval for the treatment of febrile neutropenia (FN), a biosimilar regulatory framework, and current updates on the clinical trials (CTs).
引用
收藏
页码：924 / 932
页数：9
相关论文
共 50 条
  • [21] Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study
    Arash Jenabian
    Ali Ehsanpour
    Seyed Mohammad Reza Mortazavizadeh
    Jahangir Raafat
    Mohsen Razavi
    Adnan Khosravi
    Sharareh Seifi
    Babak Salimi
    Nassim Anjidani
    Hamidreza Kafi
    Supportive Care in Cancer, 2022, 30 : 8151 - 8158
  • [22] Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study
    Ludwig, Heinz
    Bokemeyer, Carsten
    Aapro, Matti
    Boccadoro, Mario
    Gascon, Pere
    Denhaerynck, Kris
    Krendyukov, Andriy
    Abraham, Ivo
    MacDonald, Karen
    FUTURE ONCOLOGY, 2019, 15 (08) : 897 - 908
  • [23] Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
    Girma Tekle Gebremariam
    Atalay Mulu Fentie
    Kebede Beyene
    Beate Sander
    Gebremedhin Beedemariam Gebretekle
    BMC Health Services Research, 22
  • [24] Prevention and Treatment of Chemotherapy-Induced Neutropenia with the Biosimilar Filgrastim: A Non-Interventional Observational Study of Clinical Practice Patterns
    Tesch, Hans
    Ulshoefer, Thomas
    Vehling-Kaiser, Ursula
    Ottillinger, Bertram
    Bulenda, Dietmar
    Turner, Matthew
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (04) : 146 - 152
  • [25] Clinical factors predicting return emergency department visits in chemotherapy-induced febrile neutropenia patients
    Heo, Sejin
    Jeon, Kyeongman
    Park, Boram
    Ko, Ryoung-Eun
    Kim, Taerim
    Hwang, Sung Yeon
    Yoon, Hee
    Shin, Tae Gun
    Cha, Won Chul
    Lee, Se Uk
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2023, 67 : 90 - 96
  • [26] Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Stu
    Kowalyszyn, Ruben D.
    Fein, Luis E.
    Richardet, Martin E.
    Varela, Mirta S.
    Ortiz, Eduardo
    Micheri, Cristian
    Zarba, Juan J.
    Kahl, Susana
    Klimovsky, Ezequiel
    Federico, Andrea A.
    Cassini, Jorge H.
    Cortese, Gustavo
    Lago, Nestor
    JCO GLOBAL ONCOLOGY, 2022, 8 (01)
  • [27] Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015
    Weycker, Derek
    Bensink, Mark
    Wu, Hongsheng
    Doroff, Robin
    Chandler, David
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2115 - 2120
  • [28] Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
    Zsuzsanna Kahan
    Daniela Grecea
    Martin Smakal
    Sergei Tjulandin
    Igor Bondarenko
    Luca Perjesi
    Andras Illes
    Karoly Horvat-Karajz
    Ildiko Aradi
    BMC Cancer, 19
  • [29] Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
    Kahan, Zsuzsanna
    Grecea, Daniela
    Smakal, Martin
    Tjulandin, Sergei
    Bondarenko, Igor
    Perjesi, Luca
    Illes, Andras
    Horvat-Karajz, Karoly
    Aradi, Ildiko
    BMC CANCER, 2019, 19
  • [30] Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments
    Gascon, Pere
    Aapro, Matti
    Ludwig, Heinz
    Rosencher, Nadia
    Boccadoro, M.
    Turner, Matthew
    MacDonald, Karen
    Muenzberg, Michael
    Abraham, Ivo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 77 (03) : 198 - 200
12345